310 related articles for article (PubMed ID: 16159624)
1. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.
Ong YE; Menzies-Gow A; Barkans J; Benyahia F; Ou TT; Ying S; Kay AB
J Allergy Clin Immunol; 2005 Sep; 116(3):558-64. PubMed ID: 16159624
[TBL] [Abstract][Full Text] [Related]
2. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
Corren J; Diaz-Sanchez D; Saxon A; Deniz Y; Reimann J; Sinclair D; Davancaze T; Adelman D
Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383
[TBL] [Abstract][Full Text] [Related]
3. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
4. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
Corren J; Shapiro G; Reimann J; Deniz Y; Wong D; Adelman D; Togias A
J Allergy Clin Immunol; 2008 Feb; 121(2):506-11. PubMed ID: 18269927
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
[TBL] [Abstract][Full Text] [Related]
8. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M
Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
[TBL] [Abstract][Full Text] [Related]
11. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
[TBL] [Abstract][Full Text] [Related]
12. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.
Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D
Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583
[TBL] [Abstract][Full Text] [Related]
13. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics.
Noga O; Hanf G; Kunkel G; Kleine-Tebbe J
Int Arch Allergy Immunol; 2008; 146(1):66-70. PubMed ID: 18087163
[TBL] [Abstract][Full Text] [Related]
14. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment.
van Rensen EL; Evertse CE; van Schadewijk WA; van Wijngaarden S; Ayre G; Mauad T; Hiemstra PS; Sterk PJ; Rabe KF
Allergy; 2009 Jan; 64(1):72-80. PubMed ID: 19076931
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.
Gauvreau GM; Arm JP; Boulet LP; Leigh R; Cockcroft DW; Davis BE; Mayers I; FitzGerald JM; Dahlen B; Killian KJ; Laviolette M; Carlsten C; Lazarinis N; Watson RM; Milot J; Swystun V; Bowen M; Hui L; Lantz AS; Meiser K; Maahs S; Lowe PJ; Skerjanec A; Drollmann A; O'Byrne PM
J Allergy Clin Immunol; 2016 Oct; 138(4):1051-1059. PubMed ID: 27185571
[TBL] [Abstract][Full Text] [Related]
16. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders.
Foroughi S; Foster B; Kim N; Bernardino LB; Scott LM; Hamilton RG; Metcalfe DD; Mannon PJ; Prussin C
J Allergy Clin Immunol; 2007 Sep; 120(3):594-601. PubMed ID: 17765756
[TBL] [Abstract][Full Text] [Related]
17. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
Holgate S; Casale T; Wenzel S; Bousquet J; Deniz Y; Reisner C
J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888
[TBL] [Abstract][Full Text] [Related]
18. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
[TBL] [Abstract][Full Text] [Related]
20. Attainments in atop: special aspects of allergy and IgE.
Milgrom H
Adv Pediatr; 2002; 49():273-97. PubMed ID: 12214775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
